Aptevo reports mipletamig 93% ORR, zero CRS in frontline AML Phase 1b/2 trial at ASH 2025

Aptevo Therapeutics Inc.

100% of patients free of cytokine release syndrome (CRS) across cohorts 1-3.
93% overall response rate (ORR) among evaluable patients; 87% CR/CRi, 73% CR.
60% of MRD-evaluable CR/CRi patients achieved MRD-negative status; 43% of ORR patients had TP53 mutation.
Median patient age 75; triplet regimen (mipletamig + AZA/VEN) generally well tolerated.
Data presented Dec 8 at ASH 2025; RAINIER trial continues enrollment at additional dose levels.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.